Purpose Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC); however, the subsequent development of resistance emphasizes the necessity of overcoming this therapeutic limitation. MET amplification is one of the major resistance mechanisms in EGFR-mutant NSCLC, bypassing EGFR inhibition by activating cell survival, proliferation, and metastasis. Combining MET and EGFR TKIs is thus emerging as a promising therapeutic strategy to overcome resistance to EGFR TKIs.
Materials and Methods This study investigated the combination of the selective MET TKI vabametkib and a third-generation EGFR TKI lazertinib in MET-amplified EGFR TKI resistance models. Inhibition of downstream signaling and cell proliferation by vabametkib plus lazertinib was evaluated in osimertinib-resistant NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010) by western blot and CellTiter-Glo assay.
Results In vitro studies demonstrated that vabametkib plus lazertinib synergistically inhibited EGFR/MET phosphorylation, leading to markedly enhanced anti-proliferative effects through downstream phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase pathway blockade. To investigate the antitumor effects in vivo, we employed two patient-derived xenograft models (YHIM-1035(1) and YHIM-1053) harboring MET amplification, as characterized by whole-exome sequencing or droplet digital polymerase chain reaction. Consistent with the in vitro findings, treatment with vabametkib plus lazertinib produced pronounced suppression of tumor growth in both models through a synergistic mechanism.
Conclusion These findings establish vabametkib plus lazertinib as a promising strategy for MET-amplified NSCLC, currently under evaluation in an ongoing phase II clinical trial (NCT05541822).
Citations
Citations to this article as recorded by
Organoid models in lung cancer research: A multidimensional perspective from basic biology to precision medicine Ruili Zhao, Huifang Cheng, Shiyu Mei, Haoran Li, Longhua Zhang, Ya Li Letters in Drug Design & Discovery.2026; 23(3): 100424. CrossRef
AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems Fuxiang Wang, Hongqian Jiang, Yan Chen, Zhe Zhang, Zhen Wang, Wei Liu, Fusheng Chi Journal of Oncology Pharmacy Practice.2026;[Epub] CrossRef
Anlotinib combined with almonertinib reverses almonertinib resistance in lung adenocarcinoma by inhibiting the c-MET/PI3K/AKT pathway Dingdan Lu, Bo Peng, Weiwei Ouyang World Journal of Surgical Oncology.2026;[Epub] CrossRef